New Oral NLRP3 Inhibitor Cuts Inflammation 86% in Early Heart Disease Trial
BioAge's BGE-102 enters Phase 2 with dramatic Phase 1 CRP reductions, targeting cardiovascular risk through inflammasome blockade.
Summary
BioAge Labs has launched a mid-stage clinical trial testing BGE-102, an oral pill designed to reduce chronic inflammation linked to heart disease. The drug works by blocking NLRP3, a key driver of harmful inflammation in the body. In earlier Phase 1 testing, BGE-102 cut levels of hsCRP — a major blood marker of cardiovascular risk — by a median of 86% at select doses. The new Phase 2 trial, called QUELL-CV, will enroll around 160 adults at elevated cardiovascular risk over 12 weeks, testing three different daily doses against placebo. Results are expected in late 2026. If confirmed, a drug that dramatically lowers inflammatory biomarkers with a once-daily pill could become a meaningful new tool for reducing heart disease risk.
Detailed Summary
Chronic low-grade inflammation is a central driver of cardiovascular disease, and few approved therapies directly target it. BioAge Labs is now advancing BGE-102, an oral NLRP3 inflammasome inhibitor, into a Phase 2 trial aimed at proving it can meaningfully reduce cardiovascular inflammation in at-risk adults.
The QUELL-CV trial is a randomized, double-blind, placebo-controlled study enrolling approximately 160 adults with elevated cardiovascular risk. Participants will receive one of three once-daily oral doses — 30 mg, 60 mg, or 90 mg — or placebo for 12 weeks. The primary endpoint is percent change in high-sensitivity C-reactive protein (hsCRP), a well-established blood biomarker of systemic inflammation and cardiovascular risk. Secondary endpoints include the proportion of participants achieving hsCRP normalization below 2 mg/L, along with cardiometabolic and imaging biomarkers.
The Phase 1 data behind this trial are striking. In healthy volunteers and participants with obesity and elevated inflammation, BGE-102 achieved median hsCRP reductions of 86% at selected doses. The drug also showed favorable pharmacokinetics and a tolerable safety profile, supporting progression to larger trials. The company describes these reductions as potentially best-in-class among NLRP3 inhibitors in development.
BGE-102's mechanism — blocking the NLRP3 inflammasome — is scientifically significant. NLRP3 activation drives the production of inflammatory cytokines including IL-1β and IL-18, which contribute to atherosclerosis and other age-related diseases. An orally available, brain-penetrant small molecule targeting this pathway has potential implications beyond cardiovascular disease, including metabolic and neuroinflammatory conditions.
Caveats apply. Phase 1 results do not guarantee Phase 2 success, and hsCRP reduction, while predictive, is a surrogate endpoint rather than a clinical outcome like heart attack reduction. Topline data are expected in the second half of 2026, which will be the critical readout for this program.
Key Findings
- BGE-102 reduced hsCRP by a median of 86% at select doses in Phase 1 trials in high-risk adults.
- Phase 2 QUELL-CV trial enrolls 160 cardiovascular-risk adults across three oral doses vs placebo over 12 weeks.
- Primary endpoint is hsCRP reduction; secondary endpoints include hsCRP normalization below 2 mg/L.
- BGE-102 is brain-penetrant, suggesting potential future applications in neuroinflammation beyond heart disease.
- Topline Phase 2 data anticipated in the second half of 2026.
Methodology
This is a news report from Longevity.Technology summarizing a company press release about a Phase 2 clinical trial initiation. Evidence is based on Phase 1 company-disclosed data, not yet peer-reviewed. The source is a credible longevity-focused outlet, but independent verification of Phase 1 claims is warranted.
Study Limitations
Phase 1 data are company-reported and not peer-reviewed; 86% hsCRP reduction is preliminary and may not replicate at scale. hsCRP is a surrogate biomarker, not a hard cardiovascular outcome. The trial's 12-week duration cannot assess long-term safety or event reduction.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.